Comment on "Decoy Receptor 3 Expression in AsPC-1 Human Pancreatic Adenocarcinoma Cells via the Phosphatidylinositol 3-Kinase-, Akt-, and NF-κB-Dependent Pathway"

Wei Wang, Weimin Sun and Lurong Zhang

*J Immunol* 2009; 183:2203; doi: 10.4049/jimmunol.0990053
http://www.jimmunol.org/content/183/4/2203.1

**References**
This article cites 2 articles, 1 of which you can access for free at:
http://www.jimmunol.org/content/183/4/2203.1.full#ref-list-1

**Subscriptions**
Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscriptions

**Permissions**
Submit copyright permission requests at:
http://www.aai.org/ji/copyright.html

**Email Alerts**
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/cgi/alerts/etoc
Comment on “Decoy Receptor 3 Expression in AsPC-1 Human Pancreatic Adenocarcinoma Cells via the Phosphatidylinositol 3-Kinase-, Akt-, and NF-κB-Dependent Pathway”

In the article published by Pei-Hsuan Chen and Chia-Ron Yang in the December 15, 2008 issue of *The Journal of Immunology* (1), the authors reported that the human pancreatic cancer cell line PANC-1 did not express the DcR3 protein. Our group has been focusing on the role of DcR3 in human pancreatic cancer for several years. We detected DcR3 expression of some pancreatic cancer cell lines, including AsPC-1 and PANC-1, by ELISA, and our results indicated that AsPC-1 cells expressed DcR3 protein at ~60 ng/ml and PANC-1 cells also expressed DcR3 protein at ~3 ng/ml. We also found that the DcR3 expression peaked after 48 h of incubation. To prove that PANC-1 cells express DcR3, immunoprecipitation was also used and the result was similar to that from the ELISA (Fig. 1).

In our laboratory, we used an ELISA to detect DcR3 according to the protocol previously reported. The Abs of DcR3 that we used for the ELISA were purchased from Alexis Biochemicals. The immunoprecipitation protocol was described in Dr. Zhang’s article published in *Journal of Immunological Methods* (2).

Wei Wang,* Weimin Sun,† and Lurong Zhang†

*Department of General Surgery
Second Affiliated Hospital of Fujian Medical University
Quanzhou, Fujian, People’s Republic of China
†Department of Radiation Oncology
University of Rochester Medical Center
Rochester, NY, 14620

References

www.jimmunol.org/cgi/doi/10.4049/jimmunol.0990053

Response to Comment on “Decoy Receptor 3 Expression in AsPC-1 Human Pancreatic Adenocarcinoma Cells via the Phosphatidylinositol 3-Kinase-, Akt-, and NF-κB-Dependent Pathway”

The comment from Dr. Wei Wang on our article (1) mentioned a similar trend of DcR3 expression in the human pancreatic cancer cell line AsPC-1 and PANC-1. Both of our results indicated the large amount of DcR3 expression in AsPC-1 cells after 48 h of incubation and the minor level in PANC-1 cells. This trend was also reported by other researchers not only in mRNA but also protein levels (2, 3). However, a different ELISA system might contribute to the variety of DcR3 concentration between us. We used a commercial Duo-Set ELISA development system (catalog number DY142; R&D Systems) to detect DcR3 expression levels, and all of our results were comprehended within the detection range of this kit, which limited the analytic concentration below 12 ng/ml in accordance with the manufacturer’s suggestion. Compared with the figure included with the letter of comment, we can find an almost 10 ratio different detection range between the two systems. In this condition, undetectable DcR3 levels in PANC-1...
cells were measured in our system. A similar result has been reported by another group (2).

We appreciate the kind recommendation from this comment and welcome further remarks from researchers.

Chia-Ron Yang

School of Pharmacy
College of Medicine
National Taiwan University
Taipei, Taiwan

References

www.jimmunol.org/cgi/doi/10.4049/jimmunol.0990054